Advertisement
U.S. Markets closed
S&P Futures
5,887.75 -8.50 (-0.14%) Dow Futures
43,133.00 -44.00 (-0.10%) Nasdaq Futures
20,474.75 -44.75 (-0.22%) Russell 2000 Futures
2,250.50 -5.00 (-0.22%) Crude Oil
70.27 -0.29 (-0.41%) Gold
2,743.60 +4.70 (+0.17%)
Prelude Therapeutics Incorporated (PRLD)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Follow
At close: 04:00PM EDT
After hours:
| Previous Close | 1.9000 |
| Open | 1.9300 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 1.7400 - 1.9300 |
| 52 Week Range | 1.6600 - 6.8000 |
| Volume | |
| Avg. Volume | 279,473 |
| Market Cap | 97.944M |
| Beta (5Y Monthly) | 1.47 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- MT Newswires
Prelude Therapeutics Says PRT3789 Shows 'Encouraging Signs' in Phase 1 Trial; Shares Fall
Prelude Therapeutics Says PRT3789 Shows 'Encouraging Signs' in Phase 1 Trial; Shares Fall
- Clinical Trials Arena
MSD discontinues two Phase III Keytruda trials
MSD is axing two Phase III Keytruda trials after they failed to meet the primary and secondary endpoints.
- Simply Wall St.
We're Keeping An Eye On Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, although...
Advertisement
Advertisement
Advertisement
© 2024 Yahoo. All rights reserved.